Human C-reactive protein (CRP) is a classical, acute phase serum protein synthesized by the liver in response to infection, inflammation, or trauma. CRP binds to microbial antigens and damaged cells, opsonizes particles for phagocytosis and regulates the inflammatory response by the induction of cytokine synthesis. These activities of CRP depend on its ability to activate complement and to bind to Fc␥ receptors (Fc␥R). The goal of this study was to elucidate amino acid residues important for the interaction of CRP with human Fc␥RI (CD64) and Fc␥RIIa (CD32). Several mutations of the CRP structure were studied based on the published crystal structure of CRP. 
C-reactive protein (CRP)
1 is a member of the ancient pentraxin protein family (1) . Classical pentraxins share several features including a cyclic arrangement of five (or in a few cases six) identical non-covalently bound subunits, calciumdependent ligand binding sites in each subunit, and high sequence similarity (2) . Although there is little overall structural resemblance between CRP and immunoglobulin, CRP exhibits multiple functional similarities to antibodies (reviewed in Ref.
3). These include recognition of ligands, activation of complement via the classical pathway, binding to receptors on phagocytic cells, induction of cytokine synthesis, and enhancement of phagocytosis. These functional similarities are explained by the shared ability of CRP and IgG to interact with complement component C1q and with Fc␥ receptors (Fc␥R) I and II. Conservation of its cyclic pentameric structure, calcium-dependent binding, and phosphocholine (PC) binding capability throughout evolution (4) suggest an important biological role for CRP.
In vivo experiments have implicated CRP in protection against infection, regulation of systemic and local inflammatory reactions, clearance of autoantigens, and prevention of systemic autoimmune disease (reviewed in Refs. 3 and 5) .
Fc␥R are well characterized as important to antibody-mediated immunity and when cross-linked by bound IgG antibodies, trigger cellular responses. It has been previously demonstrated that CRP binds to human Fc␥RI on U-937 cells and transfected COS-7 cells (6, 7) . This finding has recently been confirmed by surface plasmon resonance studies, which established a high affinity interaction between Fc␥RI and CRP (K D ϭ 0.81 ϫ 10 Ϫ9 M) (8) . Our laboratory has recently shown that Fc␥RII is the second receptor for CRP on human leukocytes and myeloid cells (9, 10) . The binding of CRP to Fc␥RIIa was recently confirmed by confocal fluorescence microscopy (11) and the rosetting of CRP opsonized erythrocytes by Fc␥RIIa-transfected COS-7 cells (12) .
Interactions between IgG of different subclasses and Fc␥R have been extensively characterized by using chimeric antibodies, site-directed mutagenesis, and most recently co-crystallization of the human IgG1 Fc fragment with soluble Fc␥RIII (13) (14) (15) (16) . The selection of the sites to be mutated on CRP was based on the current knowledge regarding the sites in IgG that interact with Fc␥R, the assumption of functional homology of the similar amino acid motifs in IgG and CRP and the published crystal structure of CRP (17) . Because aggregated IgG completely inhibits CRP binding to Fc␥R on cells, and human IgG1 completely inhibits CRP binding to Fc␥RI in surface plasmon resonance (8) , it is likely that the sites on Fc␥R that bind IgG and CRP are similar. Based on sequence homology with IgG (18), we previously identified a specific amino acid position, Leu 176 , that is important for CRP binding to Fc␥RI. Mutation of Leu 176 to Glu eliminates CRP binding to Fc␥RI while preserving binding to Fc␥RIIa. Another group has identified several amino acid residues in CRP important in binding to C1q (19, 20) .
CRP is an important molecule involved in multiple aspects of the response to infection and other inflammatory stimuli. In-creasing our understanding of the basic biology of the interaction of CRP with receptors on inflammatory cells will increase our understanding of the inflammatory process and may lead to the development of new anti-inflammatory molecules, warranting investigation of the interaction of CRP at the molecular level. The homogeneity of human CRP in the human population dictates that any investigation into the structure-function relationships of CRP requires alternate methods than studying naturally occurring polymorphisms. This study uses oligonucleotide-directed mutagenesis to characterize the interaction of CRP with Fc␥RI and Fc␥RIIa, and with C1q. The mutant and wild-type (wt) recombinant proteins were expressed in the baculovirus system (21) 
MATERIALS AND METHODS
Mutagenesis-Mutant CRP DNAs were generated with the PCRmediated QuikChange mutagenesis kit (Stratagene, La Jolla, CA). A 1.01-kb BamHI-BglII fragment was subcloned from HLCRP23 (a generous gift from J. E. Volanakis, University of Alabama at Birmingham), into the baculovirus transfer vector pBlueBac4 (pBB4, Invitrogen, Carlsbad, CA) and maintained in DH5-␣ Escherichia coli (Promega, Madison, WI). This construct was used as the CRP template for all PCR, except L176A, which was subcloned into pFastBac1 (Invitrogen).
Primer sequences were designed based on the published genomic DNA sequence for CRP (22) . Primer pairs were designed with single, double, or triple base changes to produce single amino acid changes upon translation. The primers were synthesized either on an Oligo 1000 DNA Synthesizer (Beckman Instruments, Inc., Fullerton, CA) or by the Center for Genetics in Medicine at the University of New Mexico (Albuquerque, NM). Mutant CRP plasmid DNA was produced by PCR with the CRP containing plasmid as template. To remove the template DNA (which consists of wild-type sequence), PCR products were then subjected to DpnI digestion at 37°C for 3 h to preferentially eliminate bacterial DNA, i.e. methylated and hemimethylated DNA. Mutant CRP DNAs were used to transform DH5-␣ E. coli (Promega) for clonal expansion according to the manufacturer's directions.
The identities of mutant DNAs were confirmed via direct sequencing (Sequenase V. 2.0, Amersham Biosciences) or by cycle sequencing at the Center for Genetics in Medicine at the University of New Mexico (Albuquerque, NM). Large-scale DNA plasmid preparations were then performed by cesium chloride gradient centrifugation followed by phenol-chloroform extraction and ethanol precipitation.
Recombinant Protein Expression-Mutant CRP DNAs in the baculovirus transfer vector were co-transfected with baculovirus DNA (Bac-N-Blue, Invitrogen) into Sf9 insect cells (Invitrogen) using the MaxBac Transfection Kit (Invitrogen), except for L176A, which was constructed with the BactoBac Expression System (Invitrogen). Sf9 insect cells were maintained in supplemented Grace's media (Invitrogen), according to the manufacturer's instructions, and additionally supplemented with heat-inactivated 10% fetal calf serum (Hyclone Laboratories, Ogden, UT). Transfection stocks were plaque purified according to the directions for the Transfection Kit as described (23) . Recombinant plaques were selected based on phenotype and ␤-galactosidase reporter gene expression. Individual recombinant plaques were picked and used to infect additional Sf9 cells plated at a density of 5 ϫ 10 5 cells/well in 12-well tissue culture plates. Viral DNA was isolated from the culture supernatants according to the manufacturer's directions and verified by PCR. Viral stocks were re-purified by plaque assay if they contained non-recombinant as well as recombinant virus. Viral stocks comprised of pure, recombinant virus were used to inoculate successively larger cultures of Sf9 cells to create high-titer stocks of recombinant virus. The titers of the viral stocks were determined by plaque assay on Sf9 cells. The high-titer viral stocks were then used to inject Trichoplusia ni (Lepidoptera) larvae (Entopath, Easton, PA) for large scale mutant protein expression as previously described (7, 21) , except that the proteins were not metabolically labeled. Larvae were processed for CRP recovery as previously described (21) . Briefly, a crude larval lysate containing protease inhibitors was applied to a PC-Sepharose affinity chromatography column in the presence of 2 mM calcium. The bound CRP was eluted from the column with a pH 7.4, 10 mM Tris, 75 mM citrate buffer and dialyzed into pH 7.4, 20 mM Tris, 0.15 M NaCl, 10 mM CaCl 2 (TNC). The purity of the CRP was evaluated with 5-20% polyacrylamide gradient SDS-gel electrophoresis.
Reagents and Antibodies-Human CRP was prepared from human pleural fluids as previously described (24) . PC-conjugated BSA (15:1 molar ratio) (PC-BSA) and C-polysaccharide (PnC) were prepared in our laboratory as described (25, 26) . The anti-CRP monoclonal antibody (mAb) 2C10 was graciously provided by Dr. Larry Potempa (ImmTech, Evanston, IL) and used as a hybridoma tissue culture supernatant. 8C10 and 9H8 are anti-CRP mAb that recognize denatured or "neo" determinants on CRP (27) and were kindly provided in purified form by Dr. Henry Gewurz (Rush Medical College, Chicago, IL). C1q was purchased from Sigma. The following antibodies were purchased: HRPsheep anti-human CRP from The Binding Site (San Diego, CA); sheep anti-human CRP, HRP-goat anti-human C3, and HRP-goat anti-mouse IgG from ICN (Irvine, CA); FITC-goat anti-mouse (GAM) IgG F(abЈ) 2, affinity purified PE-GAM IgG F(abЈ) 2 , PE-C1KM5 (anti-CD32 mAb), and PE-10.1 (anti-CD64 mAb) from Caltag (Burlingame, CA); mouse mAb to human C1q from Quidel (San Diego, CA); AT10 (an anti-CD32 mAb) and FITC-AT10 from Serotec (Raleigh, NC); FITC-FLI8.26 (an anti-CD32 mAb) from BD Pharmingen (San Diego); anti-CD64 mAb 197 and anti-CD32 mAbs IV.3 and 32.2 from Medarex (Annandale, NJ). FITC-FLI8.26 was pre-absorbed against mock-transfected COS-7 cells for 30 min on ice prior to use, to reduce nonspecific binding.
Enzyme-linked Immunosorbent Assays (ELISA)-Immulon 2 microtiter plates (Dynatech Laboratories, Alexandra, VA) were used throughout. The blocking buffer was 0.5% BSA in TNC, the dilution buffer was 0.1% BSA in TNC, and the washing buffer was 0.05% Tween 20 in TNC. The plates were developed with ABTS substrate (1 mg/ml 2,2Ј-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) and 0.005% H 2 O 2 in McIlvaine's citric acid-phosphate buffer (pH 4.6) and absorbance was measured at 405 nm using an ELISA plate reader.
Isolated CRP was quantitated by sandwich ELISA using a human CRP standard curve as described (21) as well as by BCA assay (Pierce Chemical Co., Rockford, IL). WT and mutant CRP were tested for native structure by ELISA as previously described (21) . Briefly, ELISA plates were coated with 5 g/ml PC-BSA, blocked, and incubated with 5 g/ml CRP. The mAb 2C10, which recognizes native determinants, was used to determine PC-BSA binding ability. The mAb 8C10 and 9H8 were used to determine the exposure of denatured determinants, which are not detectable on ligand-bound human CRP (27) . All mAb were detected using HRP-goat anti-mouse IgG and ABTS substrate.
Human, WT, and mutant CRP were compared for ligand binding using an inhibition assay. ELISA plates were coated with 10 g/ml PC-BSA or PnC and blocked. CRP (20 ng/ml) was mixed with free PC (10 to 100 M) and applied to the wells. CRP binding was detected using HRP anti-CRP and ABTS substrate.
WT and mutant CRP were compared for C1q binding and complement activation on PC-BSA-coated ELISA wells. Plates were coated with PC-BSA at 5 g/ml in TNC. The plates were blocked and incubated with CRP samples, diluted from 0.10 to 3.0 g/ml. The plates were washed and incubated with C1q at 5 g/ml for 1 h at room temperature. Binding was detected using anti-C1q mAb at 5 g/ml, HRP-conjugated anti-mouse IgG and ABTS as substrates. For the complement activation assay normal human serum diluted 1/20 was added in place of C1q, and plates were incubated for 15 min at 37°C. Plates were developed with HRP-rabbit anti-human C3 and substrate. Heat-inactivated (56°C, 30 min) normal human serum was used as a control.
Cell Culture-The COS-7 cell line (American Type Culture Collection, Bethesda, MD) was used to express either Fc␥RI or Fc␥RIIa. The cells were grown in a humidified incubator at 37°C in 5% CO 2 in DMEM (Sigma) supplemented with HEPES and 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT). K-562 cells were also obtained from the American Type Culture Collection and grown in RPMI 1640 media (Sigma) supplemented with 10% calf serum (Hyclone), 2 mM L-glutamine, and 50 g/ml gentamicin.
Receptor Expression-For the cell transfections, the cDNA clone for the R131 allele of human Fc␥RIIa in the pcDSR␣296 transient transfection vector (28) was obtained from Dr. Kevin Moore (DNAX Research Institute, Palo Alto, CA). The plasmid DNA pRc/CMV-Fc␥RIaI (the IgG high-affinity receptor) was a gift from Dr. Robert P. Kimberly (University of Alabama at Birmingham, Birmingham, AL). Cells were trans-fected with the GenePORTER transfection reagent from Gene Therapy Systems, Inc. (San Diego, CA) as described (9) CRP Receptor Binding Assay-The CRP receptor binding assay has been described previously (9) . Cells in phosphate-buffered saline containing 0.05% azide and 0.1% globulin-free BSA (PAB) were incubated with CRP diluted in PAB for 1 h on ice, then washed twice and incubated with mAb2C10 culture supernatant for 30 min on ice. Cells were washed twice with PAB, and incubated with PE-GAM IgG F(abЈ) 2 (1 g/10 6 cells) or FITC-GAM IgG F(abЈ) 2 for 30 min on ice. The cells were then washed and resuspended in PAB for analysis by flow cytometry on a BD Biosciences FACSCalibur flow cytometer equipped with Cell Quest software (BD Biosciences, Mountain View, CA). The samples were analyzed by forward and side scatter to exclude dead cells, and a minimum of 20,000 cells were collected.
The mutants were tested for binding to both Fc␥RI and Fc␥RII with transfected COS-7 cells expressing Fc␥RI or Fc␥RIIa and K562 cells, a human erythroleukemia cell line that expresses Fc␥RIIa as its only Fc␥R. K562 cells were used for initial screening of mutants for Fc␥RIIa binding. Those mutant proteins showing a change from wild type for receptor binding were verified by binding assay to transfected COS-7 cells. Several recombinants showing no change from the wild type were, however, initially tested in both the cell culture and transfection systems, to ensure a predictive value of the cell culture system before transfections with Fc␥RIIa were performed.
Data for receptor binding were collected on a BD Biosciences FACSCalibur flow cytometer with CellQuest software. Analysis was performed by nonlinear regression analysis using GraphPad PRISM (GraphPad Software, Inc., San Diego, CA). For all measurements of CRP binding, the binding of 2C10 and the anti-mouse secondary antibody were subtracted. Results are presented as the change in geometric mean channel fluorescence (⌬GMCF) relative to secondary antibody controls.
Molecular Models-Models shown in Figs. 1 and 7 were produced with the program WebLab ViewerLite (Molecular Simulations, Inc.) using the crystal structure of CRP complexed with PC (Protein Data Bank code 1B09) (15) and human IgG1 Fc region obtained from cocrystallization with Fc␥RIII (PDB 1E4K) (15) .
RESULTS

Design of Mutants-We have established that CRP binds to
Fc␥RI and Fc␥RIIa on human leukocytes, myeloid cells, and transfected COS cells (7, 9, 10) . The particular sites to be mutated were chosen on the basis of sequence similarity between CRP and the regions of IgG shown to be important for Fc␥R binding (30 -32 (14) and co-crystallization (15, 16) . This region also contains residues (Pro 329 and Pro 331 ) important for human IgG1 binding to C1q (33) . Sequence homologies between CRP and serum amyloid P component (SAP) and both of these regions of IgG have been identified (Table I) . For the human pentraxins, there is a greater resemblance between CRP and the 234 -237-region of IgG, whereas SAP shows greater sequence homology with the 328 -333-region of IgG. Interestingly, these regions that are separated by a large stretch of amino acids in IgG are contiguous in CRP and SAP. The location of this proposed binding region on the A face of the CRP pentamer is shown on the bottom of Fig. 1 and a comparison of this region with the homologous regions on human IgG1 is shown on the top of Fig. 1 . Both regions show an exposed proline (colored brown). In IgG this proline is proposed to interact with Fc␥RIII in a proline sandwich with tryptophans 87 and 110 (15) .
Additional positions were chosen based on sequence differences between CRP and SAP, because SAP was expected to demonstrate a different binding activity with respect to CRP at the outset of this study. However, since the inception of the study, we have determined that SAP also binds to human Fc␥RI, Fc␥RIIa, and Fc␥RIIIb (34) . CRP is postulated to possess a binding groove, bordered on one side by an ␣-helix comprised of residues Glu 169 to Leu 176 and a loop comprised of residues Gly 177 to Asn 183 and toward the center of the pentamer by another loop comprised of residues Glu 112 to Lys 114 . This cleft is not present in SAP because of differences in amino acid identities in the homologous positions in the sequences of the two proteins (35) . Therefore, the mutagenesis encompassed some SAP-like mutants, N158D, L176Q, D169E, E170N, and N186D at individual residues within the putative binding cleft.
Verification of Mutant Molecule Integrity-Mutants were tested for preservation of conformational integrity by ELISA with mAb specific for native and denatured determinants. Mutants were further tested for ligand binding by measuring PC inhibition of binding to wells coated with PC-BSA and PnC. All of the mutants, except E170N, bound to PC-BSA and reacted with mAb 2C10, which recognizes native and denatured determinants ( Fig. 2A) . The lowest reactivity of the mutants was about 75% of normal for N186D and D169E in this assay. None of the mutants reacted with mAb (8H9 or 8C10) specific for determinants exposed on denatured CRP (27) and those tested all showed nearly identical PC inhibition of binding to PC-BSA (not shown) and PnC (Fig. 2B) .
Cell Binding-The mutant CRPs were tested for binding to Fc␥RI and Fc␥RIIa-transfected COS-7 cells. Representative binding assays are shown in Figs. 3-5 . The most dramatic change in binding was shown by T173A, in which mutation eliminated binding to Fc␥RI (Fig. 3) and drastically reduced binding to Fc␥RIIa (Fig. 4A) , when compared with the binding of WT recombinant CRP. Mutant T173A represents the first identification of a residue involved in binding of CRP to Fc␥RIIa. It also identifies another residue involved in CRP binding to Fc␥RI to add to the previous demonstration of the contribution of residue 176 in CRP binding to Fc␥RI (7) . The loss of binding of T173A to Fc␥RIIa was confirmed using K562 cells, which express Fc␥RIIa (Fig. 5) .
Mutant L176Q (Fig. 3) , and mutants D169E, D169A, Y175L, and N158D (Fig. 4) effected little discernible change in binding to either Fc␥RI or Fc␥RIIa. E170N was shown to have reduced binding to Fc␥RIIa, but the structural integrity of the protein was questionable based on low reactivity in the PC-BSA binding assay ( Fig. 2A) . L176Q, unlike the mutant L176E (7), and L176A (Table II) showed no appreciable change in binding to Fc␥RI or Fc␥RIIa (Fig. 4B) , indicating a requirement for both a neutral charge and a large side chain for the interaction with the corresponding residue on Fc␥RI. The results of binding assays with other CRP mutants are summarized in Table II . Notably, K114A showed reduced binding to Fc␥RI, but normal binding to K562 cells, and mutant N186D showed reduced binding to both Fc␥RI and K562 cells. The Y175L mutation was predicted to increase binding to Fc␥R based on sequence homology. This mutant did show increased binding to mouse Fc␥RI, based on binding studies with peritoneal macrophages from Fc␥RIIb-deficient mice (not shown). Binding to human and mouse Fc␥RII was unchanged.
C1q Binding-Mutants K114A, D112A (7, 19) , and E88A (20) have previously been identified as corresponding amino acid residues important in C1q binding. Because the C1q and Fc␥R binding sites of CRP are postulated to be on the same face of the molecule (20) , it is reasonable that certain important residues for binding may be shared not only by the Fc␥R, but among Fc␥RI and Fc␥RIIa and C1q. Our group also examined mutant K114A and found C1q binding to be high versus WT CRP (Fig. 6) , congruent with the previous findings of Agrawal and Volanakis (19) . Mutants N158D and E88A exhibited normal binding to C1q, in comparison to the previous demonstration of no change in C1q binding by mutant N158S and a slight decrease for N158A and E88A and E88Q (19) . Mutant T173A (Fig. 6 ) and mutants D169A, Y175L, L176Q, L176A, L176E, and N186D (Table II) , however, no longer bound C1q. The results of the complement activation assay measuring C3 deposition after incubation in normal human serum agreed with the C1q binding assays (not shown). E170N appeared to be a possible expression-defective variant, based on dramatically reduced binding of PC-BSA. Although binding curves were initially generated for E170N and both Fc␥R in this study, the protein was unable to bind PC-BSA soon after the flow cytometry experiments, thus calling into question the stability of the mutant. The change of this amino acid may have induced a large conformational change to disrupt the tertiary structure of the expressed protein. This mutant was, therefore, not pursued further.
The amino acid positions at which mutations were made are depicted in red on one subunit in Fig. 7 . The residues implicated in Fc␥R binding site are depicted in cyan on a second subunit, and the proposed C1q binding site is depicted in green on a third subunit, showing considerable overlap. The homology region residues 175-185 between CRP and IgG is shown in yellow.
DISCUSSION
The goals of the present study were to examine the binding sites on CRP for Fc␥RI and Fc␥RIIa and to develop mutant CRPs lacking individual binding activities. Modification of Leu 176 to Glu in a prior study by our laboratory completely abrogated CRP binding to Fc␥RI without affecting its binding to Fc␥RIIa (7). We examined this particular amino acid position again and changed Leu 176 to either Gln or Ala. CRP with Leu 176 changed to Ala had binding properties that were similar to the change to glutamate, whereas the change to glutamine resulted in no discernible change of binding interaction with Fc␥RI or Fc␥RIIa. Because the glutamine mutation changes the amino acid to the same identity as that of SAP, the observation is consistent with the finding that SAP also binds murine and human Fc␥R (7, 34, 36) . However, binding to C1q was absent in the Gln variant, as in the Glu and Ala variants of position 176. These observations support the hypothesis of Agrawal et al. (20) that an ␣-helix at amino acids 169 -176 at the C terminus of the protein, and part of a large cleft on CRP (opposite its PC-binding face), contributes part of the C1q binding site.
The amino acid residues involved in CRP binding to Fc␥RIIa were completely unknown prior to this study. LLGG motif (234 -237 EU numbering, see Kabat et al. (37) ) is part of the active site for both Fc␥RIIa and Fc␥RI binding (13, 14, 18, 30 ). Yet, the interactions for each residue are not the same for IgG and each receptor (14, 30) , as in our observation of Leu 176 in CRP. The fact that the type of amino acid change made alters the binding capability to Fc␥R indicates that our mutagenesis screen in all likelihood provides only a limited, first estimation of the identification of residues involved in CRP binding. We can, however, state that Thr 173 and Leu 176 must be important to CRP binding to Fc␥RI. Both of these residues are within the C terminus of the pentraxin ␣-helix (amino acids 169 -176) that borders a shallow pocket on the A face of CRP (35) . It was recently demonstrated that the residues involved in binding of IgG1 to Fc␥RI are within a subset of a group that are involved in binding to Fc␥RII (and Fc␥RIII) (14) . At the current time, with only a small number of CRP residues investigated, we can say that the same is not true for CRP binding to the different Fc␥R, because although mutation of Thr 173 and Asn 186 affected binding to both Fc␥RI and Fc␥RII, mutation of Lys 114 and Leu 176 only affected Fc␥RI binding.
In this study we produced mutants D169A, T173A, Y175L, and L176Q, which all eliminated C1q binding (Fig. 6 ). These are within the ␣-helix at amino acid positions 169 -176 at the C terminus of the protein that is proposed to be a major component of a C1q binding pocket (20) . N158D, D169E, and E88A did not show any difference in C1q or Fc␥R binding. It was previously reported that N158S bound normally to C1q and that N158A, E88A, and E88Q showed slightly decreased binding (20) . Whereas D169E had normal binding, mutation of Asp 169 to alanine, eliminated binding, providing support for the hypothesis that charge is important for CRP binding to C1q (18) . We further confirmed increased C1q binding and complement activation for the K114A mutant located in the Asp 112 -Lys 114 loop toward the center of the CRP pentamer. These observations help to further refine the identification of the C1q binding site by Agrawal et al. (19, 20) , which was supported by modeling (38) .
Interestingly, the K114A mutant lacked Fc␥RI binding, but retained Fc␥RIIa binding. To the degree that there appear to be multiple important residues in common among the Fc␥RI and Fc␥RIIa and C1q binding sites, one may postulate that a portion of the C1q binding site has been co-opted for binding to Fc␥R some time during the course of the evolution of the vertebrate lineage or perhaps of the mammalian lineage. The complement system existed before the emergence of adaptive immunity and has recently been suggested as being present in the dipteran insect Anopheles gambiae, based on the identification of a novel protein that is both structurally and functionally similar to complement factor C3 (39), the central component of the complement activation pathways. Members of the family of pentraxin molecules had been identified in another arthropod, horseshoe crabs (40, 41) , and recently a putative and novel Drosophila pentraxin homologue, b6, has been characterized (42) . CRP is viewed as a prototypical acute phase protein and is part of a nonspecific, initial response to tissue insult or invasion by pathogens, which would likely represent an evolutionary precursor to the innovation of a clonal host response seen in most vertebrates. The ability of CRP to activate complement would surely have conferred sufficient selective advantage to maintain its expression since the protostome-deuterostome divergence to persist through the emergence of the vertebrate lineage, to be available for co-option for use in the Fc␥R-mediated adaptive immunity response.
The modulation of binding activity through site-directed mutagenesis of CRP may be re-examined in light of recent claims that CRP does not bind to Fc␥RIIa (45) and not to Fc␥RI nor Fc␥RIIa (43) . These findings have been addressed elsewhere (8, 34, 44) , but the observations in this study provide additional evidence for Fc␥R binding by CRP. These claims argue that CRP binding to these receptors previously described by our laboratory and others was likely because of binding of the Fc portion of the antibodies used for detection (45) or contaminating IgG in CRP preparations used in binding studies (43) . If the prior claim were correct, then we should have been able to expect that mutagenesis of CRP would effect no change in demonstrable binding avidity in conjunction with an anti- FIG. 5 . Decreased binding of CRP mutant T173A to K562 cells expressing Fc␥RIIa. Recombinant CRP were tested for K562 binding to corroborate the results from binding assays for Fc␥RIIa in the transfection system. Binding assays were carried out as described for the transfected COS-7 cells, except using the K562 cell line which expresses Fc␥RIIa as its only Fc␥R. Data were fitted to a single binding site model for receptor binding. Results for other mutant CRP are summarized in Table II . body-based binding detection method. The ability to reduce, enhance, and/or eliminate binding ability by mutating recombinant CRP in this study indicates that the CRP must be able to bind Fc␥R, because the lack of binding was detected with an antibody-based detection system (2C10 mAb). Additionally, to address the latter claim, we demonstrate in this study several recombinant mutant CRPs that show minimal to no change in Fc␥R specificity. This is germane because insects do not have the capacity to express IgG that might otherwise be present in the protein preparation and detected as binding to Fc␥R. The co-crystallization of the human IgG1 Fc fragment with Fc␥RIII (15, 16) and studies of the mouse IgG2b Fc fragment and mouse Fc␥RII interactions in solution using NMR (46) have led to a model of asymmetric binding of one Fc␥R to two CH2 domains. Several other FcR have been crystallized (47, 48) and these structures were used to form a general model for Fc-Fc␥R interactions (49) . In this model, Leu 234 -Ser 239 residues in both hinge regions of the CH2 domains provide important contacts with hydrophobic regions of Fc␥R. A second major contact is a "proline sandwich" formed between Pro 329 of one CH2 domain and two Trp residues (87 and 110) on Fc␥R. Pro 329 is part of the second homology region identified in Fig. 1 . Based on these models and the data obtained from the CRP crystal structure and mutagenesis experiments, we propose that the hydrophobic region formed by the ␣-helix (Glu 169 to Leu 176 ) and adjacent loop (Gly 177 -Asn 186 ) on the A face of CRP provide the major area of contact between CRP and Fc␥R (see Fig. 1 The CRP pentamer is shown with residues 175-185 in yellow on one subunit. The residues investigated are indicated in red on a second subunit. On a third subunit the residues directly implicated by mutagenesis experiments to be involved in binding to Fc␥R are shown in cyan. The proposed C1q binding site is shown on a fourth subunit in green, based on data presented by Agrawal et al. (19, 20) and the current findings. The structure was rendered in Weblab ViewerLite. been fully characterized (14, 15) . The carbohydrate residue NAG1 at Asn 297 of IgG1 is proposed to contact Fc␥RIII (15) or to stabilize the hinge region of IgG1 (16) . CRP is not glycosylated and therefore a directly homologous interaction cannot be present.
Identification of important residues responsible for the binding interaction can guide design of CRP for modulating immune recruitment through Fc␥R, as well as by complement activation. The Fc␥R binding mutants presented here can provide additional molecular tools for future functional studies, to better understand the role of CRP in immune function through Fc␥R-mediated signaling. The mutants will allow for the study of interactions of CRP with individual Fc␥R on leukocytes. CRP is an important molecule that is involved in many aspects of the inflammatory response to infection and inflammatory stimuli. Increasing our understanding of the basic biology of the interaction of CRP with receptors on inflammatory cells will increase our understanding of the inflammatory process and may facilitate the generation of new therapeutic molecules.
